Skip to Main Content

SAN FRANCISCO — Celgene is famous for cultivating a constellation of biotech partners — companies whose fortunes are poised to be shifted by last month’s news that Bristol-Myers Squibb plans to buy Celgene in a $74 billion deal.

One of those partners is BeiGene, among the buzziest companies in China’s rising biotech sector and one that could feel ripple effects.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!